T cells and cytokines in inflamed psoriatic skin. Who's in charge?

Immunology
Simon Milling, Stefan Siebert

Abstract

Inflammation in psoriasis is driven through the IL-23/IL-17 pathway. Monoclonal antibodies targeting cytokines in the pathway have proven highly effective and are widely used in clinical practice. There is still much to learn, however, about how these pathogenic responses are controlled, particularly with respect to the highly immunologically active molecules produced by the inflamed skin tissue itself. These tissue-derived molecules, which include IL-33, play important roles in modulating chronic inflammation that we are only beginning to understand. Here we highlight new research indicating a role for IL-33 in modulating the inflammatory Th17 response in psoriasis, which may provide avenues for developing new psoriasis treatments.

References

Mar 27, 2009·The Journal of Investigative Dermatology·Antonella Di CesareFrank O Nestle
Jun 16, 2011·European Journal of Immunology·Axel J HueberIain B McInnes
Oct 27, 2016·Nature Reviews. Immunology·Foo Yew LiewHeth Roderick Turnquist
May 18, 2017·The British Journal of Dermatology·C H SmithM F Mohd Mustapa
Jan 10, 2018·Immunology·Kazuhisa FurueMasutaka Furue
Aug 23, 2018·Immunology·Aoi Akitsu, Yoichiro Iwakura
May 8, 2020·Clinical and Experimental Immunology·J M FletcherC M Smith

❮ Previous
Next ❯

Related Concepts

Related Feeds